𝔖 Bobbio Scriptorium
✦   LIBER   ✦

FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis

✍ Scribed by Cox, Edward; Laessig, Katherine

Book ID
127118473
Publisher
Massachusetts Medical Society
Year
2014
Tongue
English
Weight
456 KB
Volume
371
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Review of the Evidence for Using Bedaq
A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
✍ Gregory J. Fox, Dick Menzies 📂 Article 📅 2013 🏛 Springer Healthcare Communications 🌐 English ⚖ 600 KB

Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial limitations, in terms of their effectiveness, side-effect profile, and complexity of administration. Bedaquiline is a novel diarylquinoline antibiotic that has recently been investigated as an adjunct to existing ther